Mueller A J, Jian G, Banker A S, Rahhal F M, Capparelli E, Freeman W R
Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, La Jolla 92093-0946, USA.
Am J Ophthalmol. 1998 Feb;125(2):158-63. doi: 10.1016/s0002-9394(99)80085-3.
To investigate the effect of posterior subtenon injections of corticosteroids on intraocular pressure in a variety of ocular diseases.
We retrospectively analyzed 202 consecutive posterior subtenon corticosteroid injections (148 of methylprednisolone acetate, 80 mg, and 54 of triamcinolone acetonide, 40 mg) in 63 eyes of 55 patients (26 male, 29 female; mean age +/- SD, 60.17 +/- 26.55 years). All patients had received topical or systemic corticosteroids before the injection, and no rise in intraocular pressure had been noted. Preinjection and postinjection intraocular pressure measurements were compared by two-tailed paired t test. Statistical analysis was performed separately by patient (first injection of first injected eye), by eye (first injection of each eye), and by all injections. To detect increase in intraocular pressure during follow-up, statistical analysis was performed separately 14 to 90 days, 91 to 150 days, and 151 to 270 days after injection.
No statistically significant difference was found between preinjection and postinjection intraocular pressure measurements. A power calculation in the most stringent subanalysis (by patient) proved that there is only a 3.87% chance to statistically miss a clinically significant rise in intraocular pressure from 15 to 21 mm Hg.
Posterior subtenon injection of corticosteroids does not cause an increase in intraocular pressure. All patients in our study had been treated previously with topical or systemic corticosteroids and did not react with an excessive increase in intraocular pressure. This safety of repository corticosteroids may therefore not apply to patients whose status in responding to corticosteroids is not known.
探讨在多种眼部疾病中,球后Tenon囊下注射皮质类固醇对眼压的影响。
我们回顾性分析了55例患者(26例男性,29例女性;平均年龄±标准差,60.17±26.55岁)63只眼中连续进行的202次球后Tenon囊下皮质类固醇注射(148次注射醋酸甲基泼尼松龙,80mg,54次注射曲安奈德,40mg)。所有患者在注射前均接受过局部或全身皮质类固醇治疗,且未观察到眼压升高。注射前和注射后的眼压测量值通过双侧配对t检验进行比较。分别按患者(首次注射的第一只眼)、按眼(每只眼的首次注射)和所有注射进行统计分析。为检测随访期间眼压升高情况,在注射后14至90天、91至150天和151至270天分别进行统计分析。
注射前和注射后的眼压测量值之间未发现统计学上的显著差异。在最严格的亚分析(按患者)中的效能计算证明,从统计学上错过眼压从15至21mmHg的临床显著升高的可能性仅为3.87%。
球后Tenon囊下注射皮质类固醇不会导致眼压升高。我们研究中的所有患者此前均接受过局部或全身皮质类固醇治疗,且未出现眼压过度升高的反应。因此,长效皮质类固醇的这种安全性可能不适用于对皮质类固醇反应情况未知的患者。